Sign in →

Test Code LAB777 CA 19-9 (Cancer Antigen 19-9), Plasma or Serum

Reporting Title

CA 19-9

Methodology

Beckman Coulter DXI 800 Immunoassay System

Patient results determined by assays using different instrumentation may not comparable. 

Useful For

Used to monitor disease status of patients with pancreatic cancer who have levels of serum CA 19-9 above the cutoff at the time of diagnosis. It is also elevated with cancers of the biliary tract, gallbladder, lung, pancreas, and other gastrointestinal cancers. It is occasionally elevated in benign conditions.

Performing Laboratory

OhioHealth Laboratory Services-RMH Special Testing

Specimen Requirements

Lipemic and hemolyzed samples are not acceptable. 

 

If medically practical, patients receiving biotin supplements should discontinue use prior to sample draws. 

 

Submit only 1 of the following specimens:

 

Preferred:

Serum

Draw blood in a gold-top serum gel tube(s). Spin down and send 1 mL of serum refrigerated. 
Note:

1.A speckled-top serum gel tube (s) or a plain, red-top tube(s) is also acceptable.

2. Patients receiving therapy with mouse monoclonal antibodies may have erroneous results.

3. Indicate serum on request form.

4. Label specimen appropriately (serum).

 

Collection Instructions:

1. Serum gel tubes should be centrifuged within 2 hours of collection.

2. Red-top tubes should be centrifuged and aliquoted within 2 hours of collection.

 

Alternate:

Plasma

Draw blood in a mint green-top (heparin) gel tube(s). Spin down and send 1 mL of heparinized plasma refrigerated. 

Note:  1. Patients receiving therapy with mouse monoclonal antibodies may have erroneous results.

2. Indicate plasma on request form.

3. Label specimen appropriately (plasma).

 

Specimen Stability Information

Specimen Type Temperature Time
Serum and plasma Refrigerated 6 days
  Ambient  8 Hours
  Frozen  Stable

 

Specimen Transport Temperature

Refrigerate: OK

Frozen: OK

Ambient: NO

Reference Values

0.0-40.0 U/mL

Serum markers are not specific for malignancy and values may vary by methods. Patients known to be phenotypically-negative for the Lewis blood group antigen will be unable to produce the CA 19-9 antigen even in the presence of proven malignancy. Phenotyping for the Lewis antigen may be insufficient to detect true Lewis antigen-negative individuals. Even patients who are genotype-positive for the Lewis antigen may produce varying levels of CA 19-9.

Day(s) Test Set Up

Monday through Friday day shift only

Test Classification and CPT Coding

86301